{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:33:04Z","timestamp":1768689184080,"version":"3.49.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00772","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T04:25:58Z","timestamp":1571977558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder"],"prefix":"10.3389","volume":"10","author":[{"given":"Maria Rosaria Anna","family":"Muscatello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco A.","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemente","family":"Cedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fortunato","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"B1","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3664-y","article-title":"Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy","volume":"82","author":"Farshchian","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000471","article-title":"Duloxetine as an analgesic reduces opioid consumption after spine surgery: a randomized, double-blind, controlled study","volume":"33","author":"Bedin","year":"2017","journal-title":"Clin J Pain"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.07.006","article-title":"Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity","volume":"55","author":"Vaishnavi","year":"2004","journal-title":"Biol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.103382","article-title":"Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor","volume":"318","author":"Deecher","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666151117122458","article-title":"The role of levomilnacipran in the management of major depressive disorder: a comprehensive review","volume":"14","author":"Bruno","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2002.tb00234.x","article-title":"Duloxetine pharmacology: profile of a dual monoamine modulator","volume":"8","author":"Karpa","year":"2002","journal-title":"CNS Drug Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2012.693912","article-title":"Preclinical discovery of duloxetine for the treatment of depression","volume":"7","author":"Torres-Sanchez","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03772-1","article-title":"Adaptation of monoaminergic responses to phencyclidine in nucleus accumbens and prefrontal cortex following repeated treatment with fluoxetine or imipramine","volume":"958","author":"De La Garza","year":"2002","journal-title":"Brain Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1124\/mol.109.063081","article-title":"Long-term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms","volume":"77","author":"Calabrese","year":"2010","journal-title":"Mol Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300514","article-title":"Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise","volume":"29","author":"Russo-Neustadt","year":"2004","journal-title":"Neuropsychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-008-1276-7","article-title":"Basal and stress-induced modulation of activity-regulated cytoskeletal associated protein (Arc) in the rat brain following duloxetine treatment","volume":"201","author":"Molteni","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00009-6","article-title":"Descending control of pain","volume":"66","author":"Millan","year":"2002","journal-title":"Prog Neurobiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.09.012","article-title":"Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain","volume":"48","author":"Bomholt","year":"2005","journal-title":"Neuropharmacology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00754-4","article-title":"Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence","volume":"62","author":"Thor","year":"2003","journal-title":"Urology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.9.1142","article-title":"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects","volume":"31","author":"Lantz","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008810","article-title":"Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor","volume":"40","author":"Sharma","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1213","article-title":"Greist JH. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder","volume":"68","author":"Whitmyer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212245","article-title":"Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary","volume":"2013","author":"Ball","year":"2013","journal-title":"Drugs Context"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-012-0040-1","article-title":"Duloxetine: a review of its use in the management of major depressive disorder in older adults","volume":"30","author":"Dhillon","year":"2013","journal-title":"Drugs Aging"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000155815.44338.95","article-title":"Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine","volume":"25","author":"Thase","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000246216.26400.db","article-title":"Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder","volume":"26","author":"Acharya","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"B25","article-title":"Reference ID: 2860327. Cymbalta - Highlights of Prescribing Information","year":"2010"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.272","article-title":"Pharmaceutical overdose deaths, United States, 2010","volume":"309","author":"Jones","year":"2013","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother Psychosom"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0514","article-title":"Duloxetine treatment of dysthymia and double depression: an open-label trial","volume":"68","author":"Koran","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2050312114533536","article-title":"An open treatment trial of duloxetine in elderly patients with dysthymic disorder","volume":"2","author":"Kerner","year":"2014","journal-title":"SAGE Open Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07230","article-title":"A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression","volume":"73","author":"Hellerstein","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.12.026","article-title":"Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study","volume":"210","author":"Hellerstein","year":"2017","journal-title":"J Affect Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1058103","article-title":"Treatment of seasonal affective disorder with duloxetine: an open-label study","volume":"41","author":"Pjrek","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.4.517","article-title":"Duloxetine for premenstrual dysphoric disorder: a pilot study","volume":"9","author":"Mazza","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145709000066","article-title":"Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial","volume":"12","author":"Ramos","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyu062","article-title":"Open-label study of duloxetine for the treatment of obsessive-compulsive disorder","volume":"18","author":"Dougherty","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000592","article-title":"Duloxetine augmentation in resistant obsessive-compulsive disorder: a double-blind controlled clinical trial","volume":"36","author":"Mowla","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00076.x","article-title":"Open-label support for duloxetine for the treatment of panic disorder","volume":"15","author":"Simon","year":"2009","journal-title":"CNS Neurosci Ther"},{"key":"B39","article-title":"Duloxetine in military posttraumatic stress disorder","volume":"43","author":"Villarreal","year":"2010","journal-title":"Psychopharmacol Bull"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1040","article-title":"Duloxetine in obese binge eater outpatients: preliminary results from a 12-week open trial","volume":"24","author":"Leombruni","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/eat.20946","article-title":"Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial","volume":"45","author":"Guerdjikova","year":"2012","journal-title":"Int J Eat Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834bbc0d","article-title":"Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial","volume":"26","author":"Mico\u2019","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-101557","article-title":"Duloxetine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study","volume":"49","author":"Nikbakhat","year":"2016","journal-title":"Pharmacopsychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-006-6659-2","article-title":"The efficacy of duloxetine in the treatment of premature ejaculation","volume":"39","author":"Athanasios","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0905-9","article-title":"Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation","volume":"47","author":"Ozcan","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1177\/1087054712443157","article-title":"Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study","volume":"18","author":"Bilodeau","year":"2014","journal-title":"J Atten Disord"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108095715","article-title":"Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study","volume":"24","author":"Bellino","year":"2010","journal-title":"J Psychopharmacol (Oxford)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00307-5","article-title":"Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients","volume":"78","author":"Devanand","year":"2004","journal-title":"J Affect Disord"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000157","article-title":"Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study","volume":"34","author":"Bruno","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.08.015","article-title":"Antidepressants for cognitive impairment in schizophrenia\u2013a systematic review and meta-analysis","volume":"159","author":"Vernon","year":"2014","journal-title":"Schizophr Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000196","article-title":"Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study","volume":"34","author":"Bruno","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/da.22511","article-title":"psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments","volume":"33","author":"Lee","year":"2016","journal-title":"Depress Anxiety"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006533","article-title":"Duloxetine versus other anti-depressive agents for depression","volume":"10","author":"Cipriani","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S159800","article-title":"Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline","volume":"14","author":"Huang","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18f12254","article-title":"Relative efficacy and acceptability of antidepressant drugs in adults with major depressive disorder: commentary on a network meta-Analysis","volume":"79","author":"Andrade","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12203","article-title":"Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials","volume":"8","author":"Zhang","year":"2016","journal-title":"Asia Pac Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e0194501","DOI":"10.1371\/journal.pone.0194501","article-title":"Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: a meta-analysis","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T16:29:44Z","timestamp":1572884984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2019.00772"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00772","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"article-number":"772"}}